Biotest Past Earnings Performance
Past criteria checks 0/6
Biotest's earnings have been declining at an average annual rate of -29.8%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 9.8% per year.
Key information
-29.8%
Earnings growth rate
-28.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 9.8% |
| Return on equity | -18.1% |
| Net Margin | -12.7% |
| Next Earnings Update | 14 Nov 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biotest makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 511 | -65 | 83 | 50 |
| 31 Mar 22 | 512 | -54 | 82 | 51 |
| 31 Dec 21 | 516 | -63 | 82 | 52 |
| 30 Sep 21 | 514 | -28 | 77 | 55 |
| 30 Jun 21 | 507 | -33 | 78 | 55 |
| 31 Mar 21 | 507 | -35 | 80 | 56 |
| 31 Dec 20 | 484 | -31 | 80 | 56 |
| 30 Sep 20 | 466 | -34 | 82 | 56 |
| 30 Jun 20 | 459 | -24 | 84 | 54 |
| 31 Mar 20 | 439 | -15 | 83 | 52 |
| 31 Dec 19 | 419 | -5 | 83 | 53 |
| 30 Sep 19 | 406 | -9 | 82 | 52 |
| 30 Jun 19 | 395 | -3 | 82 | 53 |
| 31 Mar 19 | 390 | -6 | 82 | 51 |
| 31 Dec 18 | 400 | -13 | 85 | 49 |
| 30 Sep 18 | 405 | 18 | 91 | 50 |
| 30 Jun 18 | 409 | 6 | 91 | 52 |
| 31 Mar 18 | 400 | 1 | 99 | 54 |
| 31 Dec 17 | 378 | -16 | 100 | 55 |
| 30 Sep 17 | 257 | -48 | 95 | 56 |
| 30 Jun 17 | 301 | -47 | 93 | 52 |
| 31 Mar 17 | 340 | -29 | 89 | 49 |
| 31 Dec 16 | 408 | 6 | 88 | 48 |
| 30 Sep 16 | 531 | 128 | 78 | 36 |
| 30 Jun 16 | 525 | 52 | 88 | 62 |
| 31 Mar 16 | 526 | 36 | 88 | 72 |
| 31 Dec 15 | 535 | 27 | 93 | 79 |
Quality Earnings: BTTA.Y is currently unprofitable.
Growing Profit Margin: BTTA.Y is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BTTA.Y is unprofitable, and losses have increased over the past 5 years at a rate of 29.8% per year.
Accelerating Growth: Unable to compare BTTA.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BTTA.Y is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: BTTA.Y has a negative Return on Equity (-18.15%), as it is currently unprofitable.